RHONE-POULENC RORER PAKISTAN (PVT) LTD.

the company profile for Rhone-Poulenc Rorer Pakistan (Pvt) Ltd., presented purely in English, addressing its likely nature as both a manufacturer and trader, and including important historical context:

Company Profile: Rhone-Poulenc Rorer Pakistan (Pvt) Ltd.

Introduction:

Rhone-Poulenc Rorer Pakistan (Pvt) Ltd. was the Pakistani subsidiary of the global pharmaceutical company Rhone-Poulenc Rorer. It operated within the pharmaceutical sector in Pakistan, focusing on the development, production, and marketing of healthcare products.

Nature of Business (Manufacturer/Factory vs. Trader):

As a subsidiary of a major multinational pharmaceutical corporation, Rhone-Poulenc Rorer Pakistan (Pvt) Ltd. likely operated as both a manufacturer and a distributor/trader.

1. Manufacturer (Factory): It is highly probable that the company had local manufacturing facilities (a factory) in Pakistan to produce certain pharmaceutical products domestically. This is common practice for large pharma companies to serve local markets efficiently and comply with local regulations.

2. Trader/Distributor: The company would also have been involved in importing specialized pharmaceutical products from its parent company or other international sites, marketing them, and distributing them throughout Pakistan. This trading aspect involved managing supply chains, sales forces, and marketing campaigns.

Historical Context & Current Status:

It is crucial to note the historical context of the parent company:

In 1999, Rhone-Poulenc Rorer merged globally with Hoechst Marion Roussel to form Aventis.

In 2004, Aventis was acquired by Sanofi-Synthélabo, forming Sanofi-Aventis (later rebranded as simply Sanofi).

Therefore, Rhone-Poulenc Rorer Pakistan (Pvt) Ltd. as an entity operating under that specific name no longer exists. Its operations, assets, and personnel would have been integrated into the successor companies, first becoming part of Aventis Pakistan and subsequently Sanofi Pakistan Limited.

Conclusion:

Historically, Rhone-Poulenc Rorer Pakistan (Pvt) Ltd. was a significant pharmaceutical entity in Pakistan, functioning as both a manufacturer with local production facilities and a trader distributing imported and locally made medicines. Its legacy continues today through its successor company, Sanofi Pakistan Limited, which remains a major player in the country's pharmaceutical industry with both manufacturing and commercial operations.

the information regarding the products associated with the legacy company Rhone-Poulenc Rorer Pakistan (Pvt) Ltd., presented in English.

Important Context:

Rhone-Poulenc Rorer Pakistan (Pvt) Ltd. as an entity operating under that specific name is historical. Through a series of mergers:

1. Rhone-Poulenc Rorer was formed globally in 1990.

2. Rhone-Poulenc merged with Hoechst Marion Roussel in 1999 to create Aventis.

3. Aventis merged with Sanofi-Synthélabo in 2004 to create Sanofi-Aventis, which later rebranded as Sanofi.

Therefore, the operations and products previously under Rhone-Poulenc Rorer Pakistan would now fall under Sanofi-Aventis Pakistan Limited (or its current Sanofi branding in Pakistan).

Products Marketed by the Successor Company (Sanofi) in Pakistan:

While a definitive list of products specifically sold under the "Rhone-Poulenc Rorer Pakistan" name during its existence is difficult to compile accurately today, the successor company, Sanofi-Aventis Pakistan Limited, manufactures and/or markets a wide range of pharmaceutical products and vaccines. Some well-known examples include (but are not limited to):

Prescription Pharmaceuticals:

Cardiovascular:

Clexane (Enoxaparin Sodium) - Anticoagulant

Plavix (Clopidogrel) - Antiplatelet

Co-Plavix (Clopidogrel + Aspirin)

Cordarone X (Amiodarone) - Antiarrhythmic

Tritace (Ramipril) - ACE Inhibitor

Diabetes:

Lantus (Insulin Glargine) - Long-acting insulin

Apidra (Insulin Glulisine) - Rapid-acting insulin

Amaryl (Glimepiride) - Oral hypoglycemic

Toujeo (Insulin Glargine U300)

Soliqua (Insulin Glargine and Lixisenatide)

Oncology:

Taxotere (Docetaxel) - Chemotherapy

Eloxatin (Oxaliplatin) - Chemotherapy

Jevtana (Cabazitaxel) - Chemotherapy

Central Nervous System (CNS):

Stilnox / Ambien (Zolpidem Tartrate) - Sedative/Hypnotic

Internal Medicine / Anti-infectives:

Flagyl (Metronidazole) - Antibiotic/Antiprotozoal

Targocid (Teicoplanin) - Antibiotic

Peflacine (Pefloxacin) - Antibiotic (Quinolone)

Allergy:

Telfast (Fexofenadine Hydrochloride) - Antihistamine

Pain Management:

No-Spa (Drotaverine Hydrochloride) - Antispasmodic

Vaccines (often under Sanofi Pasteur):

Vaccines for Polio, Influenza, Meningitis, Rabies, Diphtheria, Tetanus, Pertussis, etc. (Specific brand names like Shanvac-B, Pediacel, Hexaxim, Verorab, etc. might be used).

Consumer Healthcare (CHC):

Enterogermina (Bacillus Clausii spores) - Probiotic

Maalox (Aluminum Hydroxide, Magnesium Hydroxide) - Antacid (A classic Rorer brand)

Please Note:

This list provides examples and is not exhaustive. Product availability and specific brand names can change.

These products are currently marketed by Sanofi-Aventis Pakistan Limited, the successor company. Some of these brands (like Flagyl, Maalox, Clexane, Taxotere) have historical ties to either Rhone-Poulenc or Rorer before the mergers.